These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 1812757)

  • 1. Molecular modeling of the HIV-2 protease.
    Gustchina A; Weber IT; Wlodawer A
    Adv Exp Med Biol; 1991; 306():549-53. PubMed ID: 1812757
    [No Abstract]   [Full Text] [Related]  

  • 2. Qualitative study of drug resistance in retroviral protease using structural modeling and site-directed mutagenesis.
    Culberson JC; Bush BL; Sardana VV
    Methods Enzymol; 1994; 241():385-94. PubMed ID: 7854190
    [No Abstract]   [Full Text] [Related]  

  • 3. Time dependent heterodimer formation leads to inhibition of HIV protease activity.
    Babé LM; Craik CS
    Adv Exp Med Biol; 1991; 306():543-7. PubMed ID: 1812756
    [No Abstract]   [Full Text] [Related]  

  • 4. Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures.
    Tong L; Pav S; Pargellis C; Dô F; Lamarre D; Anderson PC
    Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8387-91. PubMed ID: 8378311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors.
    Savarino A; Cauda R; Cassone A
    J Infect Dis; 2005 Apr; 191(8):1381-2; author reply 1382-3. PubMed ID: 15776390
    [No Abstract]   [Full Text] [Related]  

  • 6. Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptide isostere.
    Tong L; Pav S; Mui S; Lamarre D; Yoakim C; Beaulieu P; Anderson PC
    Structure; 1995 Jan; 3(1):33-40. PubMed ID: 7743130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversible oxidation of HIV-2 protease.
    Davis DA; Newcomb FM; Moskovitz J; Fales HM; Levine RL; Yarchoan R
    Methods Enzymol; 2002; 348():249-59. PubMed ID: 11885278
    [No Abstract]   [Full Text] [Related]  

  • 8. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors.
    Calugi C; Guarna A; Trabocchi A
    J Enzyme Inhib Med Chem; 2013 Oct; 28(5):936-43. PubMed ID: 22803674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates.
    Tomasselli AG; Heinrikson RL
    Methods Enzymol; 1994; 241():279-301. PubMed ID: 7854182
    [No Abstract]   [Full Text] [Related]  

  • 10. X-ray structures of retroviral proteases and their inhibitor-bound complexes.
    Ringe D
    Methods Enzymol; 1994; 241():157-77. PubMed ID: 7854176
    [No Abstract]   [Full Text] [Related]  

  • 11. Subsite preferences of retroviral proteinases.
    Dunn BM; Gustchina A; Wlodawer A; Kay J
    Methods Enzymol; 1994; 241():254-78. PubMed ID: 7854181
    [No Abstract]   [Full Text] [Related]  

  • 12. Aspartic proteases in drug discovery.
    Eder J; Hommel U; Cumin F; Martoglio B; Gerhartz B
    Curr Pharm Des; 2007; 13(3):271-85. PubMed ID: 17313361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activities of precursor and tethered dimer forms of HIV proteinase.
    Phylip LH; Griffiths JT; Mills JS; Graves MC; Dunn BM; Kay J
    Adv Exp Med Biol; 1995; 362():467-72. PubMed ID: 8540359
    [No Abstract]   [Full Text] [Related]  

  • 14. A new way of looking at aspartic proteinase structures: a comparison of pepsin structure to other aspartic proteinases in the near active site region.
    Andreeva NS; Bochkarev A; Pechik I
    Adv Exp Med Biol; 1995; 362():19-32. PubMed ID: 8540318
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationships of human immunodeficiency virus protease with eukaryotic aspartic proteases.
    Lin XL; Lin YZ; Tang J
    Methods Enzymol; 1994; 241():195-224. PubMed ID: 7854179
    [No Abstract]   [Full Text] [Related]  

  • 16. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus.
    Wlodawer A; Gustchina A; Reshetnikova L; Lubkowski J; Zdanov A; Hui KY; Angleton EL; Farmerie WG; Goodenow MM; Bhatt D
    Nat Struct Biol; 1995 Jun; 2(6):480-8. PubMed ID: 7664111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of human immunodeficiency virus protease cleavage sites in proteins.
    Chou KC
    Anal Biochem; 1996 Jan; 233(1):1-14. PubMed ID: 8789141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular modeling of the structure of FIV protease.
    Gustchina A
    Adv Exp Med Biol; 1995; 362():479-84. PubMed ID: 8540361
    [No Abstract]   [Full Text] [Related]  

  • 19. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
    Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
    J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes.
    Sui Z; Salto R; Li J; Craik C; Ortiz de Montellano PR
    Bioorg Med Chem; 1993 Dec; 1(6):415-22. PubMed ID: 8087563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.